FDA approval of semaglutide for MASH

The US Food and Drug Administration (FDA) has approved semaglutide (Wegovy, Novo Nordisk) for the treatment of metabolic-associated steatohepatitis (MASH) — also known as metabolic dysfunction-associated steatohepatitis — with moderate to advanced liver fibrosis (stage F2–F3). This is the first GLP-1 receptor agonist to receive FDA approval for MASH, expanding the therapeutic indications for semaglutide beyond type 2 diabetes and obesity.

The approval follows the earlier FDA approval of resmetirom (Rezdiffra) in March 2024, which was the first drug approved specifically for MASH. Semaglutide now becomes the second agent licensed for this condition and the first GLP-1 agonist with a MASH indication.

Supporting evidence

The approval was supported by data from multiple clinical studies. The Phase 3 FLOW trial (NCT03819153), published in The Lancet, evaluated semaglutide 1.0 mg weekly in patients with chronic kidney disease and type 2 diabetes, and while not specific to MASH, it demonstrated renoprotective effects that broadened understanding of semaglutide's organ-protective properties.

Key MASH-specific data came from a Phase 2b trial published in The New England Journal of Medicine (2021), in which weekly subcutaneous semaglutide at doses of 0.1, 0.2, 0.3, and 0.4 mg was evaluated in 320 patients with MASH and stage F1–F3 fibrosis. The trial found that 40% of patients receiving the 0.4 mg dose achieved MASH resolution without worsening of fibrosis, compared with 5% on placebo. However, the proportion of patients with fibrosis improvement was not significantly different from placebo at any dose.

Novo Nordisk subsequently conducted additional Phase 3 studies to support the MASH indication, building on these findings to demonstrate histological improvement in a larger patient population.

UK context

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has also approved semaglutide (Wegovy) for MASH with moderate to advanced fibrosis, making it available for this indication in the UK. The National Institute for Health and Care Excellence (NICE) appraisal process for NHS funding of semaglutide for MASH is ongoing.

For research peptide context, semaglutide remains a prescription-only medicine (POM) in the UK. It is not legal to supply semaglutide without a prescription, and the MHRA has actively enforced against improper supply channels.

What this means for peptide researchers

The FDA and MHRA approvals of semaglutide for MASH represent a significant expansion of the GLP-1 receptor agonist therapeutic class into hepatology. Key implications:

  • Mechanistic breadth: The approval underscores that GLP-1 receptor agonists have effects beyond glycaemic control and weight loss, including direct and indirect hepatoprotective mechanisms.
  • Dose considerations: The approved dose for MASH may differ from the obesity indication, and researchers should consult the prescribing information for specifics.
  • Combination potential: With multiple agents now approved for MASH (resmetirom and semaglutide), combination peptide therapy approaches are an active area of investigation.
  • Pipeline implications: Other GLP-1 and dual/triple agonists — including survodutide (GLP-1/glucagon), retatrutide (GLP-1/GIP/glucagon), and pemvidutide (GLP-1/glucagon) — are also being studied for MASH, suggesting the indication will become increasingly competitive.

Related compounds

Researchers interested in GLP-1 agonists for metabolic liver disease may also want to review our compound profiles for semaglutide, survodutide, retatrutide, and pemvidutide.

Bottom line

The FDA approval of semaglutide for MASH marks a milestone in peptide therapeutics, extending the clinical utility of GLP-1 receptor agonists to serious liver disease. For researchers, it highlights the expanding therapeutic scope of this peptide class and the growing competitive landscape in metabolic hepatology. As always, semaglutide is a licensed prescription medicine — this article is for research and educational purposes only and does not constitute medical advice.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.